Compare DexCom, Inc. (DXCM) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs NIO Inc. — how do they compare? DexCom, Inc. trades at $83.71 (market cap $31.86B), while NIO Inc. trades at $3.61 (market cap $8.62B). The key difference: DexCom, Inc. is far larger — about 3.7× NIO Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and NIO Inc. for 81 Days on average.
| DXCM | NIO | |
|---|---|---|
Market Cap | $31.86B | $8.62B |
Volume | 3,607,070 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $7.46 |
52-Week Low | $54.84 | $3.37 |
Typical Hold Time | 62 Days | 81 Days |
Enterprise Value | $31.32B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
NIO trades at $3.54, up 1.72% today but near a 52-week low, with a bearish technical signal. Revenue grew to $87.49B in 2025, yet net losses persist at -$15.57B, though margins improved. Recent Q3 2026 deliveries rose 25.4%, and a strategic battery-swap partnership with Geely aims to expand network utilization, valued at $2.38B.
The outlook hinges on scaling profitability amid a brutal EV price war. Analysts see 76% upside to a $6.23 target, but high debt and cash burn pose risks. Sentiment is mixed, with news highlighting growth potential against competitive and macroeconomic headwinds in China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
